Tango Therapeutics Inc research snapshot
TNGX AI stock analysis reads Tango Therapeutics as a clinical-stage precision oncology company whose PRMT5 plus pan-RAS combination showed a 92% objective response rate in a small study of heavily pretreated MTAP-deleted pancreatic cancer patients, reported on June 8, 2026. The analysis is not a certain price prediction. At the August 4, 2026 cutoff, the latest verified reading used here was $27.10 on August 3 at 1:32 PM EDT, down 0.08 from the $27.18 July 31 close, with a market capitalization near $4.40 billion after the June 2026 offering increased shares outstanding to 162,329,210 per the SEC EDGAR Form 424B5. The stock surged 53% on the June 8 data release, priced an upsized about $600 million offering at $30.00 per share that closed June 11 with about $566.5 million of estimated net proceeds, and has since cooled into a consolidation roughly 21% below the $34.39 52-week high. Cash and investments were $379.84 million as of March 31, 2026, and the company stated the offering proceeds plus existing cash fund operations into 2030. The core question is whether the planned phase III trial in first-line MTAP-deleted pancreatic cancer converts early response data into a registrational path before competitive PRMT5 and RAS combinations and a 29.5% short position close in. This is informational research and not investment advice.
Current price
$27.10 at the August 3, 2026, 1:32 PM EDT reading, down 0.08 or 0.29% from the $27.18 July 31 close, within a session range reported near $25.94 to $27.79 after opening at $26.83
Market cap
About $4.40 billion, calculated as $27.10 times 162,329,210 shares outstanding after the June 2026 offering per SEC EDGAR Form 424B5; StockAnalysis.com reports $3.92 billion using a pre-offering share count of 144.65 million
AI score
65 / 100
Rating
High-risk clinical-stage biotech with strong pipeline momentum, a deep cash runway, and very high short interest
Trend status
Pullback from the $34.39 June high into consolidation, holding above the 100-day and 200-day moving averages but below the 20-day average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Tango Therapeutics is a clinical-stage precision oncology company using synthetic lethality to develop targeted cancer therapies, led by the PRMT5 inhibitor vopimetostat combined with Revolution Medicines pan-RAS inhibitors. It has no approved products and recurring revenue comes mainly from collaboration milestone payments. | Medium |
| Moat | The potential moat comes from proprietary synthetic lethality biology, composition of matter and method patents around PRMT5 inhibition in MTAP-deleted tumors, and a head start in combining PRMT5 with RAS inhibitors. This is unproven until regulatory approval and faces competitors including Amgen and the former Mirati program now at Bristol Myers Squibb. | Low |
| Management | Malte Peters became President and CEO in January 2026 with a mandate to move programs toward registration and commercialization. The team includes founder and Executive Chairman Barbara Weber, President of R and D Adam Crystal, and CFO Matthew Gall. Robert Azelby joined the board in June 2026. Management executed a well-timed about $600 million offering in June 2026, funding operations into 2030. | Medium |
| Financial trend | Pre-revenue biotech with FY2025 revenue of $62.38 million, up 48.29%, and a FY2025 net loss of $101.59 million, narrower than the $130.30 million FY2024 loss. TTM net loss is about $107.23 million. Cash and investments were $379.84 million as of March 31, 2026, and after the June offering net proceeds of about $566.5 million the company stated funding runs into 2030. | Medium |
| Valuation | At $27.10 with no approved products, valuation is driven by probability-adjusted peak sales on the PRMT5 plus RAS story. At about 77x TTM revenue and about 10x book value, the market is paying for pipeline success. Analyst targets range from $24 to $69 with an average of $44.33 and median of $40, implying meaningful upside if clinical execution holds. | Medium |
| Technical trend | TNGX traded at $27.10 on August 3, below the 20-day moving average near $28.34 and just under the 50-day near $27.51, while holding above the 100-day near $24.72 and the 200-day near $17.56. The 14-day RSI was near 47, neutral, and the 14-day ADX near 16 signaled a weak, consolidating trend after the June spike. | Medium |
| Risk level | Key risks are clinical trial failure in the phase III program, regulatory delay or redesign, dilution from a 29.5% short position and future financing, competitive PRMT5 and RAS combinations, small-sample data that may not replicate, and the binary outcomes typical of clinical-stage biotech investing. | High |
| AI confidence | Medium-high confidence for technical levels, financial runway math, offering details, and risk identification, which cross-validated across StockAnalysis.com, SEC EDGAR, and Barchart. Lower confidence for clinical probability of success, registration timelines, and peak sales estimates. | Medium data confidence |
| Investment certainty | Low certainty. TNGX has a strong early clinical signal, analyst support, and a deep cash runway, but outcomes are inherently binary. The very high short interest creates squeeze potential on positive data and downside risk on any setback. Position sizing must account for the possibility of large capital loss. | Low |
TNGX AI stock forecast
The TNGX AI stock forecast uses scenario ranges around the $27.10 August 3, 2026 reading and the analyst consensus of $44.33. It does not claim that AI can predict a specific future price. The bullish case requires the phase III first-line trial to advance cleanly, a confirmed regulatory path, and durable data at the H2 2026 readouts. The base case assumes pipeline progress with periodic financing events and dilution. The bearish case assumes clinical setbacks, competitive displacement, or a high short position turning over.
$50 to $70
More likely if the phase III first-line MTAP-deleted pancreatic cancer trial initiates and enrolls well, the H2 2026 vopimetostat lung cancer data and TNG456 glioblastoma data read positive, regulators align on a registrational path, and a high-value partnership or strong response durability forces shorts to cover.
$30 to $45
More likely if vopimetostat progresses through the phase III and registration pathway with incremental readouts, Tango continues to fund growth through periodic equity raises, and the stock trades in line with the analyst average target of $44.33 and peer clinical-stage precision oncology companies.
$10 to $18
More likely if the phase III study misses endpoints, the FDA requires additional trials or a redesign, competitive PRMT5 plus RAS programs advance faster, the small-sample 92% ORR data does not replicate, or short sellers press the stock during a clinical or regulatory lull despite the cash runway.
TNGX AI technical analysis
TNGX AI technical analysis starts from the $27.10 reading on August 3, 2026 used for this August 4 static page. Barchart data showed the stock above the 5-day average near $26.90, below the 20-day average near $28.34, just under the 50-day average near $27.51, and well above the 100-day near $24.72 and the 200-day near $17.56, confirming a long-term uptrend inside a short-term pullback after the June spike and offering. The 14-day RSI was near 47.22 on Barchart and 47.34 on StockAnalysis.com, neutral. The 14-day ADX near 16.20 with negative directional index above positive directional index signaled a weak, consolidating short-term trend, while the 50-day ADX near 28.28 kept the medium-term uptrend intact. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $27.10 | StockAnalysis.com real-time quote at the August 3, 2026, 1:32 PM EDT reading, down 0.08 or 0.29% from the $27.18 July 31 close within a session range near $25.94 to $27.79 after opening at $26.83. |
| Near support | $25.85 to $25.94 | Support zone around the July 29 close of $25.85 and the August 3 intraday low of $25.94 reported by StockAnalysis.com. A decisive close below this zone would open a test of the 100-day average. |
| Secondary support | $24.72 | The 100-day moving average reported by Barchart on August 3, 2026. TNGX last tested this area in early July, and it is the first major floor below the recent consolidation. |
| Near resistance | $28.34 | The 20-day moving average reported by Barchart on August 3, 2026. The stock closed below it for the pullback period, so reclaiming it is the first bullish step. |
| Next resistance | $30.00 to $31.48 | The June 2026 offering price of $30.00 and the July 10 intraday high of $31.48. This zone was the trading range before the mid-July slide. |
| 50-day moving average | About $27.51 | Barchart reported the 50-day moving average near $27.51 on August 3, 2026, matching StockAnalysis.com at $27.51. The stock is trading essentially at this level, making it a key decision point. |
| 200-day moving average | About $17.56 | Barchart reported the 200-day trend line near $17.56 on August 3, 2026, matching StockAnalysis.com. TNGX is roughly 54% above it, reflecting the extraordinary rally off the $5.77 52-week low. |
| Momentum | RSI near 47, ADX near 16 | The 14-day RSI was near 47.22 on Barchart and 47.34 on StockAnalysis.com, neutral. The 14-day ADX near 16.20 indicated a weak trend with negative directional index at 19.60 above positive at 15.90 on Barchart, while the 50-day ADX near 28.28 kept the medium-term uptrend valid. |
| Volume | About 2.45 million 20-day average shares | Barchart listed the 20-day average volume near 2.45 million shares and StockAnalysis.com near 2.43 million on August 3, 2026. June volume spiked to over 21 million shares on the data release and the offering, so traders should watch whether any breakout comes on above-average volume. |
| Volatility | 14-day ATR near $1.82 | Barchart reported the 14-day average true range near $1.82, about 6.7% of the share price, and 14-day historical volatility near 61%, reflecting the high volatility typical of a clinical-stage biotech with a large short position. |
| Invalidation | Close below $24.72, then $17.56 | A daily close below the 100-day moving average near $24.72 would signal a deepening pullback. A close below the 200-day average near $17.56 would negate the long-term uptrend built since the early 2026 lows. |
TNGX AI trading strategy
The TNGX AI trading strategy is a rules-based framework, not personalized advice. It combines binary clinical catalysts, a very high short interest that can cause sharp squeezes, technical confirmation, position sizing, and clear invalidation levels.
Map the Q2 2026 earnings date of August 5, 2026, the planned phase III first-line initiation, and the H2 2026 vopimetostat lung cancer and TNG456 glioblastoma readouts. A positive event with above-average volume reclaiming the 20-day average near $28.34 and then the $30.00 to $31.48 zone would signal renewed momentum and short-covering risk.
Clinical-stage biotech moves sharply on binary events, and the 29.5% short position amplifies both squeezes and cascades. Define a maximum loss before each catalyst and do not add risk into a readout with an undefined invalidation.
Look for TNGX to hold the 50-day average near $27.51 and reclaim the 20-day average near $28.34 with rising volume. A clean break above $30.00 and then $31.48 would confirm the pullback has ended and reopen a path toward the $34.39 high.
A daily close below $25.85 weakens the setup, and a close below the 100-day average near $24.72 should reduce confidence in the immediate trend. Treat the 200-day average near $17.56 as the long-term trend guardrail.
Track cash runway and dilution from quarterly filings, phase III enrollment and data timelines, competitive PRMT5 plus RAS programs, the 42.72 million share short position, insider and institutional ownership changes, and analyst rating changes.
Lower conviction if a key trial misses its primary endpoint, the FDA requires a redesign, Tango raises capital at distressed levels, or the small-sample 92% ORR data fails to replicate. The stock can gap down 30% or more on negative binary events despite the strong cash runway.
Investment research summary
Tango Therapeutics discovers and develops precision oncology treatments that target genetic vulnerabilities in cancer cells through synthetic lethality. Its lead program combines the PRMT5 inhibitor vopimetostat with Revolution Medicines pan-RAS inhibitors for MTAP-deleted pancreatic cancer, a genetically defined population with high unmet need.
The potential moat depends on proprietary synthetic lethality biology, composition of matter and method patents around PRMT5 inhibition, clinical data exclusivity, and a first-mover position in MTAP-deleted tumors. It is unproven until approval and will face competition from Amgen, the former Mirati program now at Bristol Myers Squibb, and other PRMT5 and RAS combination developers.
The thesis fails if the 92% ORR from 12 efficacy-evaluable patients does not replicate in the larger phase III first-line study, the FDA requires redesign or additional trials, competitive PRMT5 plus RAS programs advance faster, or the company burns its about $946 million pro forma cash without reaching value-inflection milestones.
Malte Peters, who became CEO in January 2026, is shifting Tango from research focus to registration and commercialization. The leadership includes founder and Executive Chairman Barbara Weber, President of R and D Adam Crystal, and CFO Matthew Gall. The team raised about $600 million in June 2026 at $30.00 per share and added Robert Azelby to the board, showing execution and capital markets credibility.
Precision oncology and biomarker-driven therapy are a long-term secular trend in cancer treatment. The synthetic lethality approach and the new pan-RAS inhibitor class are reshaping pancreatic cancer care, and MTAP-deleted cancers represent roughly 60,000 patients a year, about 20,000 of them pancreatic cancer.
At about $4.40 billion market cap with no approved products, TNGX trades at a premium to many clinical-stage biotechs, around 77x TTM revenue, reflecting enthusiasm around the 92% ORR data and the phase III plan. Analyst targets of $24 to $69 with an average of $44.33 imply a wide outcome range consistent with binary biotech risk, and the 29.5% short position adds extra volatility.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TNGX price | $27.10 at the August 3, 2026, 1:32 PM EDT reading, down 0.08 or 0.29% from the $27.18 July 31 close, within a session range near $25.94 to $27.79 after opening at $26.83 | StockAnalysis.com real-time quote | August 4, 2026 |
| Market capitalization | About $4.40 billion, calculated as $27.10 times 162,329,210 shares outstanding after the June 2026 offering per SEC EDGAR Form 424B5; StockAnalysis.com reports $3.92 billion using a pre-offering share count of 144.65 million | SEC EDGAR Form 424B5 and StockAnalysis.com quote | August 4, 2026 |
| Shares outstanding | 162,329,210 shares immediately after the June 2026 offering, up from 144,162,543 as of March 31, 2026 | SEC EDGAR Form 424B5 | June 10, 2026 |
| June 2026 offering | 18,166,667 shares and 1,833,395 pre-funded warrants at $30.00 per share, with about $566.5 million of estimated net proceeds, expected to close June 11, 2026, and stated to fund operations into 2030 | SEC EDGAR Form 424B5 and June 2026 8-K | June 10, 2026 |
| June 8, 2026 clinical data | vopimetostat plus daraxonrasib showed a 92% objective response rate, 90% six-month PFS rate, and 100% disease control rate in 12 efficacy-evaluable patients with second and third-line MTAP-deleted pancreatic cancer as of May 28, 2026, and vopimetostat plus zoldonrasib showed a 52% ORR and 74% six-month PFS in 27 patients | Tango Therapeutics study result call and press release | June 8, 2026 |
| FY2025 revenue | $62.38 million, up 48.29% from $42.07 million in FY2024, matching SEC EDGAR XBRL | StockAnalysis.com financials and SEC EDGAR XBRL | August 4, 2026 |
| FY2025 net loss | -$101.59 million in FY2025, narrower than -$130.30 million in FY2024, with TTM net loss of about -$107.23 million | StockAnalysis.com financials | August 4, 2026 |
| Cash and investments | $379.84 million as of March 31, 2026, including $157.83 million cash and $222.01 million short-term investments, with $32.79 million of total debt and net cash of $347.05 million | StockAnalysis.com balance sheet | August 4, 2026 |
| Pro forma cash after June offering | About $946 million, calculated as $379.84 million of March 31, 2026 cash and investments plus about $566.5 million of estimated June 2026 offering net proceeds, with the company stating funding into 2030 | SEC EDGAR Form 424B5 and StockAnalysis.com balance sheet | June 10, 2026 |
| EPS (TTM) | -$0.86 per StockAnalysis.com statistics, with the financials page listing TTM EPS of -$0.83 | StockAnalysis.com statistics and financials | August 4, 2026 |
| Cash runway | Funded into 2030 per the June 2026 offering filing, based on current operating plan, after the company previously guided to cash runway into 2028 on the June 8 call | SEC EDGAR Form 424B5 and June 8, 2026 call | June 10, 2026 |
| Analyst consensus | Strong Buy with an average target of $44.33 across 13 analysts, low $24, median $40, high $69, with 11 Strong Buy, 1 Buy, and 1 Hold | StockAnalysis.com forecast | July 30, 2026 |
| Recent analyst actions | Canaccord raised to $46 on July 30, Mizuho raised to $40 on July 17, J.P. Morgan initiated Overweight at $46 on July 15, Jefferies upgraded to Buy at $60 on June 25, Guggenheim maintained $32, and the June actions included H.C. Wainwright to $66 and Leerink to $69 | StockAnalysis.com forecast and news feed | July 30, 2026 |
| Short interest | 42.72 million shares short, about 29.53% of reported shares outstanding and 61.41% of float, with about 9.28 days to cover | StockAnalysis.com statistics | August 4, 2026 |
| Ownership | 1.25% owned by insiders and 77.03% owned by institutions, with a reported float of 69.56 million shares | StockAnalysis.com statistics | August 4, 2026 |
| Valuation check | About 68.98x TTM revenue per StockAnalysis.com and about 77x TTM revenue using the SEC post-offering share count, about 10.01x book value, with EV of about $3.58 billion per StockAnalysis.com | StockAnalysis.com statistics | August 4, 2026 |
| 52-week range and performance | 52-week range $5.77 to $34.39, up about 317.61% over the trailing 52 weeks, beta 1.15, with the stock up about 207% year to date | StockAnalysis.com quote and statistics | August 4, 2026 |
| Upcoming earnings | Q2 2026 earnings estimated for August 5, 2026 before market open | StockAnalysis.com statistics | August 4, 2026 |
| Technical snapshot | 5-day SMA near $26.90, 20-day SMA near $28.34, 50-day SMA near $27.51, 100-day SMA near $24.72, 200-day SMA near $17.56, 14-day RSI near 47.22 on Barchart and 47.34 on StockAnalysis.com, 14-day ADX near 16.20, 14-day ATR near $1.82, 14-day historical volatility near 61% | Barchart and StockAnalysis.com technical snapshots | August 4, 2026 |
This TNGX AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 4, 2026 and can be wrong. Clinical-stage biotechnology investments carry risk of total capital loss, and the market capitalization here uses the SEC EDGAR post-offering share count of 162,329,210 shares, which differs from the StockAnalysis.com pre-offering count of 144.65 million shares.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
